Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

Rhea-AI Summary

Precision BioSciences, Inc. (Nasdaq: DTIL) will publish financial results for Q1 2023 and provide a business update on May 9, 2023.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005091/en/

Investor and Media Contact:

Mei Burris

Director, Investor Relations and Finance

Mei.Burris@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

When will Precision BioSciences publish its financial results for Q1 2023?

Precision BioSciences will publish its financial results for Q1 2023 on May 9, 2023.

What is the stock ticker symbol of Precision BioSciences?

The stock ticker symbol of Precision BioSciences is DTIL.

What type of company is Precision BioSciences?

Precision BioSciences is a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies.

What will the business update include?

The business update is expected to provide information on the company's recent developments, progress, and future plans.